Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-79 (Cancelled)

Claim 80 (new) A method for improving the size or appearance of a closed wound comprising administering to the closed wound, orally administering, administering by injection or some combination thereof, a therapeutically effective amount of a composition comprising a suitable pharmaceutical carrier and at least one non-steroidal anti-inflammatory agent, wherein administering the composition improves the size or appearance of the closed wound.

Claim 81 (new) A method for improving the size or appearance of a closed wound comprising administering to the closed wound, orally administering, administering by injection or some combination thereof, a therapeutically effective amount of a composition comprising a suitable pharmaceutical carrier and at least one cyclooxygenase inhibitor, at least one NF-kB inhibitor, at least one non-steroidal prostaglandin E2 inhibitor, or a combination thereof.

Claim 82 (new) The method of claim 80, wherein the closed wound is a normal scar, a hypertrophic scar, a keloid scar, a Dupuytren's contracture, a Peyronnie's Disease, a reactive scar, an excessive post-operative scar or a fibrotic scar.

Claim 83 (new) The method of claim 81, wherein the closed wound is a normal scar, a hypertrophic scar, a keloid scar, a Dupuytren's contracture, a Peyronnie's Disease, a reactive scar, an excessive post-operative scar or a fibrotic scar.

Claim 84 (new) The method of claim 80, wherein the at least one non-steroidal antiinflammatory agent comprises a cyclooxygenase inhibitor; a NF-kB inhibitor; a prostaglandin E2 inhibitor; or a combination thereof.

Claim 85 (new) The method of claim 84, wherein the cyclooxygenase inhibitor comprises acetylsalicylic acid; aryl, substituted or unsubstituted aralkyl, allyl, and substituted or unsubstituted, linear, branched, or cyclic alkyl esters of acetylsalicylic acid; sodium salicylate; ibuprofen; celecoxib; rofecoxib; flufenamic acid; indomethacin; nabumetone; naproxen; or pharmaceutically acceptable salts or combinations thereof.

Claim 86 (new) The method of claim 84, wherein the NF-kB inhibitor comprises salicylic acid; aryl, substituted or unsubstituted aralkyl, allyl, and substituted or unsubstituted, linear, branched, or cyclic alkyl esters of salicylic acid; sulindac sulfide; sulindac sulfone; sulfasalazine; or pharmaceutically acceptable salts or combinations thereof.

Claim 87 (new) The method of claim 80, wherein the at least one non-steroidal antiinflammatory agent is administered in an amount from about 0.1 to about 10 percent by weight of the pharmaceutically acceptable carrier.

Claim 88 (new) The method of claim 81, wherein the at least one cyclooxygenase inhibitor, at least one NF-kB inhibitor, at least one non-steroidal prostaglandin E2 inhibitor, or a combination thereof is administered in an amount from about 0.1 to about 10 percent by weight of the pharmaceutically acceptable carrier.

Claim 89 (new) The method of claim 80, wherein the non-steroidal anti-inflammatory agent is present in a thermal insulating material, a gel, a hydrogel, or a sponge.

Claim 90 (new) The method of claim 81, wherein the at least one cyclooxygenase inhibitor, at least one NF-kB inhibitor, at least one non-steroidal prostaglandin E2

inhibitor, or a combination thereof is present in a thermal insulating material, a gel, a hydrogel, or a sponge.

Claim 91 (new) The method of claim 89, wherein the thermal insulating material is AVOGEL.

Claim 92 (new) The method of claim 89, wherein the at least one non-steroidal antiinflammatory agent is present in an amount of up to about 40 percent of the weight of the thermal insulating material, the gel, the hydrogel, or the sponge.

Claim 93 (new) The method of claim 80, further comprising administering at least one agent selected from the group consisting of an anti-irritant, an anti-microbial agent, an anti-prurient agent, a deodorant agent and combinations thereof.

Claim 94 (new) The method of claim 81, further comprising administering at least one agent selected from the group consisting of an anti-irritant, an anti-microbial agent, an anti-prurient agent, a deodorant agent and combinations thereof.

Claim 95 (new) The method of claim 94, wherein the anti-irritant comprises diphenhydramine, calamine, or a C₃-C₄ diol.

Claim 96 (new) The method of claim 94, wherein the deodorant comprises aluminum zirconium trichlorohydrex or zinc acetate.

Claim 97 (new) The method of claim 94, wherein the antimicrobial agent comprises a metallic compound or aluminum zirconium trichlorohydrex.

Claim 98 (new) The method of claim 94, wherein the non-steroidal anti-inflammatory agent and the agent of claim 94 are present in a thermal insulating material, a gel, a hydrogel, or a sponge.

Claim 99 (new) The method of claim 98, wherein the thermal insulating material is AVOGEL.

Claim 100 (new) The method of claim 98, wherein the non-steroidal anti-inflammatory agent and the agent of claim 94 are present in an amount of up to about 40 percent of the weight of the thermal insulating material, the gel, the hydrogel, or the sponge.

Claim 101 (new) The method of claim 80, wherein the non-steroidal anti-inflammatory agent is present in an amount from about 40 micrograms to about 400 micrograms per square centimeter of the tissue comprising a closed wound.

Claim 102 (new) The method of claim 101, further comprising oral administration of at least one agent selected from the group consisting of anti-irritant, anti-microbial, anti-prurient agent, non-steroidal prostaglandin E2 inhibitor, deodorant agent, and combinations thereof.

Claim 103 (new) A kit for improving the size or appearance of a closed wound comprising:

a hydrogel;

at least one non-steroidal anti-inflammatory agent effective for improving the size or appearance of a closed wound; and

a suitable pharmaceutical carrier.

Claim 104 (new) The kit of claim 103, wherein the at least one non-steroidal anti-inflammatory agent is a direct or indirect inhibitor of cyclooxygenase and comprises acetylsalicylic acid; aryl, substituted or unsubstituted aralkyl, allyl, and substituted or unsubstituted, linear, branched, or cyclic alkyl esters of acetylsalicylic acid; sodium salicylate; ibuprofen; celecoxib; rofecoxib; flufenamic acid; indomethacin; nabumetone; naproxen; or pharmaceutically acceptable salts or combinations thereof.

Claim 105 (new) The kit of claim 103, wherein the at least one non-steroidal anti-inflammatory agent is a direct or indirect inhibitor of NF-kB and comprises salicylic acid; aryl, substituted or unsubstituted aralkyl, allyl, and substituted or unsubstituted, linear, branched, or cyclic alkyl esters of salicylic acid; sulindac sulfide; sulindac sulfone; sulfasalazine; or pharmaceutically acceptable salts or combinations thereof.

Claim 106 (new) The kit of claim 103, wherein the hydrogel is AVOGEL.

Claim 107 (new) The kit of claim 103, further comprising a sterile solution for mixing two or more members selected from the group consisting of the hydrogel; the at least one non-steroidal anti-inflammatory agent; and a suitable pharmaceutical carrier.

Claim 108 (new) The kit of claim 103, further comprising at least one agent selected from the group consisting of a metallic anti-microbial agent, an anti-prurient agent, a non-steroidal prostaglandin E2 inhibitor, a deodorant agent, and combinations thereof.